{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:07:43Z","timestamp":1774588063337,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.soc.2025.10.005","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:40:36Z","timestamp":1768336836000},"page":"271-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dendritic Cell-Based Immunotherapy for Solid Tumors"],"prefix":"10.1016","volume":"35","author":[{"given":"Camille","family":"Baumrucker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Relation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib1","first-page":"491","article-title":"Optimizing dendritic cell-based approaches for cancer immunotherapy","volume":"87","author":"Datta","year":"2014","journal-title":"Yale J Biol Med"},{"issue":"3","key":"10.1016\/j.soc.2025.10.005_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11864-005-0001-6","article-title":"Dendritic cells in melanoma immunotherapy","volume":"6","author":"Faries","year":"2005","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.10.005_bib3","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.soc.2025.10.005_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101239","article-title":"Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development","volume":"95","author":"Gautam","year":"2024","journal-title":"Mol Aspect Med"},{"key":"10.1016\/j.soc.2025.10.005_bib6","article-title":"Dendritic cell-based immunotherapy for prostate cancer","volume":"2010","author":"Jahnisch","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.soc.2025.10.005_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.4049\/jimmunol.168.4.1823","article-title":"Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway","volume":"168","author":"Janjic","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.it.2013.10.007","article-title":"Tumoricidal activity of human dendritic cells","volume":"35","author":"Tel","year":"2014","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.soc.2025.10.005_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.soc.2025.10.005_bib13","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.soc.2025.10.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells","volume":"13","author":"Sanchez-Leon","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00262-011-1143-y","article-title":"Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines","volume":"61","author":"Poschke","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.soc.2025.10.005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117858","article-title":"Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy","volume":"184","author":"Sheykhhasan","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.soc.2025.10.005_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2217\/imt.10.56","article-title":"Enhancement of dendritic cells as vaccines for cancer","volume":"2","author":"Turnis","year":"2010","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.soc.2025.10.005_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2025.10.005_bib20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-08-2729","article-title":"Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients","volume":"15","author":"Verdijk","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102438","article-title":"Lymph nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy","volume":"14","author":"Morisaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.soc.2025.10.005_bib22","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3389\/fimmu.2019.02303","article-title":"In situ vaccination by direct dendritic cell inoculation: the coming of age of an old idea?","volume":"10","author":"Castiello","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib23","first-page":"11","article-title":"Dendritic cells are associated with prognosis and survival in breast cancer","author":"Szpor","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.soc.2025.10.005_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/7827246","article-title":"Dendritic cell-based immunotherapy: the importance of dendritic cell migration","volume":"2024","author":"Song","year":"2024","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00534-011-0457-7","article-title":"Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients","volume":"19","author":"Endo","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10.1016\/j.soc.2025.10.005_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaoncol.2024.5371","article-title":"Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: a nonrandomized clinical trial","volume":"11","author":"Han","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.10.005_bib27","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.soc.2025.10.005_bib28","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","article-title":"Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial","volume":"11","author":"Yamanaka","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib29","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial","volume":"81","author":"Schellhammer","year":"2013","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1107698","article-title":"Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm","volume":"5","author":"Gulley","year":"2016","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol"},{"issue":"18","key":"10.1016\/j.soc.2025.10.005_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814347","article-title":"Emerging immunotherapy approaches for treating prostate cancer","volume":"24","author":"Meng","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.10.005_bib34","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.10.005_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.10.005_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.soc.2025.10.005_bib37","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-24-1595","article-title":"Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects","volume":"30","author":"Isaacsson Velho","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.10.005_bib38","first-page":"1","article-title":"Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy","volume":"10","author":"Graff","year":"2015","journal-title":"Core Evid"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41523-025-00742-x","article-title":"A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer","volume":"11","author":"Soliman","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jnci\/djaa021","article-title":"Putting the pieces together: completing the mechanism of action jigsaw for sipuleucel-T","volume":"112","author":"Madan","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102870","article-title":"Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy","volume":"12","author":"Falcone","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.soc.2025.10.005_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.soc.2025.10.005_bib43","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ymthe.2023.06.005","article-title":"An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40425-019-0552-x","article-title":"Multiple antigen-engineered DC vaccines with or without IFNalpha to promote antitumor immunity in melanoma","volume":"7","author":"Butterfield","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057673","article-title":"Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination","volume":"5","author":"Bol","year":"2016","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0b013e32834b58fa","article-title":"Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome","volume":"21","author":"Ridolfi","year":"2011","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib47","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat Commun"},{"issue":"17","key":"10.1016\/j.soc.2025.10.005_bib48","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.soc.2025.10.005_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1207032","article-title":"Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)\/HER2(pos) early breast cancer","volume":"6","author":"Lowenfeld","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.soc.2025.10.005_bib50","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1016\/j.soc.2025.10.005_bib51","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1128\/JVI.73.7.5402-5410.1999","article-title":"Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer","volume":"73","author":"Santin","year":"1999","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.005_bib52","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.soc.2025.10.005_bib53","article-title":"Combination of radiation therapy, Wim\u2019s tumor 1 (WT1) dendritic cell vaccine therapy, and alpha-galactosylceramide-pulsed dendritic cell vaccine therapy for end-stage small bowel cancer","volume":"16","author":"Nagai","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.soc.2025.10.005_bib54","article-title":"Complete response in recurrent end-stage pancreatic cancer after combined immune cell therapy of alpha-galactosylceramide dendritic cell vaccine therapy, wilms\u2019 tumor 1 dendritic cell vaccine and natural killer cell therapy","volume":"17","author":"Liu","year":"2025","journal-title":"Cureus"},{"issue":"22","key":"10.1016\/j.soc.2025.10.005_bib55","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1056\/NEJM200205303462219","article-title":"Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer","volume":"346","author":"Santin","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib56","article-title":"WT1 dendritic cell vaccine therapy improves immune profile and prolongs progression-free survival in end-stage lung cancer","volume":"15","author":"Nagai","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib57","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.medj.2023.04.008","article-title":"CCL19(+) dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer","volume":"4","author":"Wu","year":"2023","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.soc.2025.10.005_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.soc.2025.10.005_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004841","article-title":"Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma","volume":"10","author":"Ramamoorthi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8071","key":"10.1016\/j.soc.2025.10.005_bib62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.soc.2025.10.005_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-Vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:01:10Z","timestamp":1774580470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1055320725000894"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic Cell-Based Immunotherapy for Solid Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}